End-of-day quote
Shenzhen S.E.
06:00:00 2024-05-12 pm EDT
|
5-day change
|
1st Jan Change
|
28.94
CNY
|
-0.55%
|
|
-3.15%
|
-4.08%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
17,741
|
30,571
|
17,522
|
14,088
|
13,338
|
13,556
|
-
|
-
|
Enterprise Value (EV)
1 |
17,741
|
30,571
|
17,522
|
14,088
|
13,338
|
13,556
|
13,556
|
13,556
|
P/E ratio
|
45.7
x
|
47.7
x
|
27.5
x
|
11.8
x
|
27.4
x
|
21
x
|
17.4
x
|
13.6
x
|
Yield
|
0.48%
|
-
|
-
|
-
|
1.33%
|
1.04%
|
1.31%
|
-
|
Capitalization / Revenue
|
8.49
x
|
10.9
x
|
5.21
x
|
2.48
x
|
4.82
x
|
4.2
x
|
3.47
x
|
2.88
x
|
EV / Revenue
|
8.49
x
|
10.9
x
|
5.21
x
|
2.48
x
|
4.82
x
|
4.2
x
|
3.47
x
|
2.88
x
|
EV / EBITDA
|
28.6
x
|
34.5
x
|
19.9
x
|
8.7
x
|
16.5
x
|
14.5
x
|
11.7
x
|
9.58
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
7.98
x
|
11.2
x
|
5.4
x
|
3.34
x
|
3.04
x
|
2.42
x
|
2.15
x
|
1.84
x
|
Nbr of stocks (in thousands)
|
445,502
|
445,485
|
444,952
|
442,034
|
442,084
|
468,413
|
-
|
-
|
Reference price
2 |
39.82
|
68.62
|
39.38
|
31.87
|
30.17
|
28.94
|
28.94
|
28.94
|
Announcement Date
|
2/28/20
|
3/30/21
|
4/24/22
|
3/30/23
|
4/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
2,091
|
2,811
|
3,361
|
5,681
|
2,765
|
3,231
|
3,902
|
4,706
|
EBITDA
1 |
620.8
|
885.5
|
881.6
|
1,619
|
806.2
|
936
|
1,157
|
1,415
|
EBIT
1 |
500.2
|
740.1
|
691.9
|
1,368
|
549.1
|
738.9
|
902.2
|
1,138
|
Operating Margin
|
23.92%
|
26.33%
|
20.59%
|
24.08%
|
19.86%
|
22.87%
|
23.12%
|
24.19%
|
Earnings before Tax (EBT)
1 |
502.2
|
730.9
|
680.5
|
1,365
|
540.8
|
733.4
|
897.3
|
1,133
|
Net income
1 |
385.1
|
634.2
|
634.4
|
1,197
|
487.6
|
648.6
|
769.6
|
1,002
|
Net margin
|
18.42%
|
22.56%
|
18.88%
|
21.07%
|
17.64%
|
20.08%
|
19.72%
|
21.3%
|
EPS
2 |
0.8722
|
1.438
|
1.430
|
2.710
|
1.100
|
1.377
|
1.668
|
2.123
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
0.1923
|
-
|
-
|
-
|
0.4000
|
0.3000
|
0.3800
|
-
|
Announcement Date
|
2/28/20
|
3/30/21
|
4/24/22
|
3/30/23
|
4/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
515.8
|
760.5
|
861.1
|
819
|
655
|
852
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
130.8
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
0.3000
|
0.1500
|
0.1900
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/15/23
|
10/25/23
|
4/21/24
|
4/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
18.7%
|
25.1%
|
20.6%
|
30.8%
|
10.9%
|
11.3%
|
12.7%
|
14%
|
ROA (Net income/ Total Assets)
|
-
|
17.5%
|
13.8%
|
-
|
-
|
9.1%
|
10%
|
11%
|
Assets
1 |
-
|
3,625
|
4,581
|
-
|
-
|
7,128
|
7,696
|
9,112
|
Book Value Per Share
2 |
4.990
|
6.140
|
7.290
|
9.530
|
9.920
|
12.00
|
13.40
|
15.80
|
Cash Flow per Share
2 |
0.7000
|
2.380
|
1.490
|
3.780
|
0.7400
|
1.870
|
1.940
|
2.390
|
Capex
1 |
179
|
419
|
456
|
583
|
432
|
398
|
400
|
480
|
Capex / Sales
|
8.57%
|
14.92%
|
13.58%
|
10.26%
|
15.62%
|
12.32%
|
10.24%
|
10.2%
|
Announcement Date
|
2/28/20
|
3/30/21
|
4/24/22
|
3/30/23
|
4/21/24
|
-
|
-
|
-
|
Last Close Price
28.94
CNY Average target price
35.24
CNY Spread / Average Target +21.77% Consensus |
1st Jan change
|
Capi.
|
---|
| -4.08% | 1.89B | | -3.58% | 12.64B | | -1.48% | 8.46B | | +8.70% | 5.66B | | +25.61% | 5.27B | | -4.58% | 4.49B | | -51.80% | 3.11B | | +16.25% | 2.87B | | +30.25% | 2.31B | | +3.02% | 1.64B |
Diagnostic & Testing Substances
|